Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EDSA Edesa Biotech	$2.45 +2.3%	$2.22	$1.55 ▼ $5.00	$16.89M	0.27	20,424 shs	51,879 shs
ENVB Enveric Biosciences	$1.26 -13.1%	$1.24	$1.01 ▼ $8.40	$4.71M	0.46	106,995 shs	3.67 million shs
LPCN Lipocine	$2.98 -1.0%	$3.14	$2.68 ▼ $6.17	$16.31M	1.24	20,506 shs	19,361 shs
SYBX Synlogic	$1.48 +1.4%	$1.40	$0.90 ▼ $1.96	$17.08M	0.52	45,620 shs	5,516 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EDSA Edesa Biotech	-1.44%	+1.69%	+3.00%	+20.60%	-48.96%
ENVB Enveric Biosciences	+9.09%	+25.00%	+15.08%	+19.83%	-81.22%
LPCN Lipocine	-2.11%	-0.99%	-9.64%	-10.15%	-14.49%
SYBX Synlogic	0.00%	+4.29%	-9.88%	+27.51%	-2.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EDSA Edesa Biotech	1.8031 of 5 stars	2.0	5.0	1.9	1.7	0.6
ENVB Enveric Biosciences	2.503 of 5 stars	3.5	2.0	4.4	0.0	0.6
LPCN Lipocine	2.4047 of 5 stars	3.8	4.0	1.3	0.0	0.6
SYBX Synlogic	1.1493 of 5 stars	0.0	3.0	3.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EDSA Edesa Biotech	4.00	Strong Buy	$5.00	103.75% Upside
ENVB Enveric Biosciences	3.00	Buy	$10.00	693.65% Upside
LPCN Lipocine	3.50	Strong Buy	$9.00	202.01% Upside
SYBX Synlogic	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ENVB, SYBX, EDSA, and LPCN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
8/11/2025	LPCN Lipocine	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/27/2025	EDSA Edesa Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$5.00
6/27/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/10/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
5/29/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$8.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	$0.70 per share	N/A
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	$0.67 per share	N/A
LPCN Lipocine	$11.20M	1.44	N/A	N/A	$3.16 per share	0.94
SYBX Synlogic	$10K	1,731.60	N/A	N/A	$1.08 per share	1.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EDSA Edesa Biotech	-$6.17M	-$1.32	N/A	N/A	N/A	N/A	-162.95%	-60.33%	N/A
ENVB Enveric Biosciences	-$9.57M	-$38.38	N/A	N/A	N/A	N/A	-341.48%	-240.71%	11/12/2025 (Estimated)
LPCN Lipocine	$10K	-$0.87	N/A	∞	N/A	N/A	-23.59%	-21.91%	11/6/2025 (Estimated)
SYBX Synlogic	-$23.36M	-$0.08	N/A	N/A	N/A	N/A	-8.09%	-5.50%	11/11/2025 (Estimated)

Latest ENVB, SYBX, EDSA, and LPCN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ENVB Enveric Biosciences	-$5.25	-$0.97	+$4.28	-$0.97	N/A	N/A
8/8/2025	Q3 2025	EDSA Edesa Biotech	-$0.26	-$0.25	+$0.01	-$0.25	N/A	N/A
8/5/2025	Q2 2025	LPCN Lipocine	-$0.41	-$0.41	N/A	-$0.41	$1.00 million	$0.62 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	N/A
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EDSA Edesa Biotech	N/A	18.96	18.96
ENVB Enveric Biosciences	N/A	2.42	2.42
LPCN Lipocine	N/A	12.71	12.71
SYBX Synlogic	N/A	3.63	3.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EDSA Edesa Biotech	5.50%
ENVB Enveric Biosciences	13.82%
LPCN Lipocine	9.11%
SYBX Synlogic	63.40%

Insider Ownership

Company	Insider Ownership
EDSA Edesa Biotech	22.60%
ENVB Enveric Biosciences	1.10%
LPCN Lipocine	6.35%
SYBX Synlogic	3.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EDSA Edesa Biotech	20	7.04 million	5.45 million	Not Optionable
ENVB Enveric Biosciences	20	3.25 million	3.21 million	Not Optionable
LPCN Lipocine	10	5.42 million	5.08 million	No Data
SYBX Synlogic	80	11.70 million	11.35 million	Optionable

ENVB, SYBX, EDSA, and LPCN Headlines

Recent News About These Companies

Synlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Synlogic's executive sells shares worth $2,802

February 5, 2025 | msn.com

Synlogic Reports Q3 2024 Financial Outcomes

November 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial Results

November 13, 2024 | finanznachrichten.de

Synlogic Reports Third Quarter 2024 Financial Results

November 12, 2024 | globenewswire.com

Synlogic preps phenylketonuria drug for phase 3 after mid-stage win

November 6, 2024 | pharmaphorum.comP

Synlogic, Inc. (0A8U.L)

August 24, 2024 | nz.finance.yahoo.com

MIN.SG,0P0001I7V6,0 (MIN.SG)

August 16, 2024 | nz.finance.yahoo.com

Maintaining Hold on Synlogic Amid Strategic Reassessment and Financial Uncertainty

August 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | finanznachrichten.de

SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024

August 8, 2024 | investorplace.com

Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | globenewswire.com

Synlogic Inc.

July 21, 2024 | wsj.com

Synlogic Inc SYBX

July 21, 2024 | morningstar.comM

The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits

May 23, 2024 | investorplace.com

Hold Rating Maintained for Synlogic Amidst Setbacks and Financial Uncertainties

May 16, 2024 | markets.businessinsider.com

SYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024

May 14, 2024 | investorplace.com

Synlogic, Inc.: Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | finanznachrichten.de

Synlogic Flat on Q1 Numbers

May 14, 2024 | baystreet.ca

Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB, SYBX, EDSA, and LPCN Company Descriptions

Edesa Biotech NASDAQ:EDSA

$2.45 +0.05 (+2.25%)

Closing price 03:57 PM Eastern

Extended Trading

$2.45 0.00 (-0.16%)

As of 04:04 PM Eastern

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Enveric Biosciences NASDAQ:ENVB

$1.26 -0.19 (-13.10%)

Closing price 04:00 PM Eastern

Extended Trading

$1.22 -0.04 (-3.17%)

As of 07:59 PM Eastern

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Lipocine NASDAQ:LPCN

$2.98 -0.03 (-1.00%)

Closing price 03:59 PM Eastern

Extended Trading

$3.05 +0.07 (+2.35%)

As of 07:12 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Synlogic NASDAQ:SYBX

$1.48 +0.02 (+1.37%)

Closing price 03:57 PM Eastern

Extended Trading

$1.48 0.00 (0.00%)

As of 06:53 PM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time